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N euroreceptors are important for neurotransmission In the central nervous system. 
N eurotransmission involves the sequential binding of small molecules called "ligands" to specific 
neuroreceptors. The use ofligands radiolabeled with radioisotopes permits the evaluation ofchanges 
in neuroreceptor activity which often occur in various neurological diseases. In particular, since the 
central muscarinic-cholinergic system is known to change with aging and in Alzheimer's Disease, the 
use of ligands which can detect these changes could be ofgreat importance. In this study, the E­
(R,R)- and Z-(R,R)- isomers ofa new muscarinic-cholinergic receptor ligand based on the "BrQNP" 
structure were radiolabeled with the bromine-82 radioisotope and administered to rats by tail vein 
injection and the percent injected dose/gram tissue values calculated. At various time periods, organs 
were removed and analyzed. In addition, urine and feces were obtained and analyzed after 
administration ofthe Z-(R,R)- isomer to determine the route and kinetics of excretion. Lipid extracts 
of selected organs and excretory products from animals administered [82Br ]-Z-(R,R)-BrQNP were 
also obtained and analyzed by thin-layer chromatography. Analysis of tissue extracts demonstrate 
that the liver, heart, blood, and excretol)' products primarily contain metabolites ofZ-(R,R)-BrQNP. 
For the brain, uptake was rapid, with activity remaining constant. In addition to identification of 
unmetabolized BrQNP in brain extracts, two other compounds were formed, one less polar and one 
more polar than the parent compound. Excretion was rapid, primarily via the urinary bladder. These 
combined results suggest that the Z-(R,R) isomer of [82Br]-labeled BrQNP is metabolized in the rat 
brain. This lack of receptor binding and high presence of metabolites suggests that the Z-(R,R) 




Cerebral muscarinic cholinergic receptors (m-AChR) play an essential role in many physiological and 
behavioral responses. Thus, an interest in imaging the distribution or density of these receptors non­
invasively in vivo with external imaging techniques has developed. Changes in m-AChR have been 
implicated in a number or disease states, in addition to memory function, sleep disorders, and aging. 
One of the prerequisites for imaging the distribution or radioactive ligands is identification of the 
radiolabled species that is responsible for binding to the receptor complex. The ideal ligand would 
bind to the receptor complex and catabolic metabolites would not demonstrate receptor affinity and 
would be eliminated rapidly from the body. The metabolism of these ligands is also important in the 
quantification of the receptor complex via compartmental modeling and requires an accurate 
determination ofthe concentration of the unchanged radioligand in the plasma and tissue of interest. 
Figure 1. Structure ofQNB.
The high receptor affinity and cerebral uptake of 
radioiodinated IQNP analogues in rat studies [2­
4] suggested that the brominated analogues 
(using 82Br) may also be useful for positron 
emission tomography (PET). 
l-Azabicyclo[2.2.2]oct-3-yl a-hydroxy-a-( 1­
bromo-l-propen-3-yl)-a-phenylacetate (BrQNP, 1), is an analogue of3-quinuclidinyl benzilate (QNB, 
2) (Figure 1). III vitro high affinity binding of this ligand to mAChR and the in vivo selectivity and 
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specificity for mAChR has recently been reported [6]. Since carbon-3 of the quinuc1idinyl moiety and 
carbon-2 ofthe acetate moiety are asymmetric centers and the vinylic bromide can have either the E 
or Z configuration (Figure 2), eight different isomeric combinations of"BrQNP" are possible. Recent 
studies with iodinated QNP analogue, IQNP, have focused on identifying the most active isomers 
from the racemic mixture to determine the optimum stereochemistry which imparts the maximum 
affinity for m-AChR. The results of these studies have shown that E-(R,R)-IQNP has high affinity 
for ,mt and m4 muscarinic receptor subtypes using in vitro receptor binding assays. 




Figure 3. Structures of substrates. 
~Sn(BUh 
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For potential clinical evaluation using positron emission tomographic imaging, bromine-76 is the best 
positron-emitting radioisotope for radiolabeling BrQNP for these studies. Bromine-76 is accelerator 
produced and is not readily available. For this reason, the reactor-produced bromine-82 radioisotope 
was used. In the present study, the bromine-82-labeled E-(R,R)- and Z-(R,R)-BrQNP isomers were 
each prepared in moderate yield (ca. 40%) by reaction of the tributylstannyl substrate (Figure 3) and 
evaluated in rats. The first part of the experiment involved injection of the two bromine-82 
analogues. At various time points the rats were killed, selected organs removed, weighed and 
counted, and percent injected dose per gram oftissue values were them calculated. Because previous 
studies have indicated that the Z-(R,R)-BrQNP isomer may be of particular interest in evaluating 
receptor changes in Alzheimer's Disease, the second experiment involved lipid extraction and 
chromatographic evaluation of the radio labeled components. In addition, the urine and feces were 
collected from one group of rats administered the Z-(R,R) isomer for a period of seven days. 
The in vivo metabolism of quinuc1idinyl esters is not well understood. In the case of (R,R)-3­
quinuclidinyl4-iodobenzilate [(R,R)-4-IQNB], only the parent compound has been reported to be 
found in the homogenates of brain tissue following intravenous administration to rats. The 
predominate metabolic products ofIQNB in plasma have been reported to be hydrophilic compounds 
and assumed to be glucuronide conjugates. Studies with E-(R,R)-IQNP have shown only 
unmetabolized material in brain extracts. In this paper we report the initial evaluation of the 
metabolism ofZ-(R,R)-BrQNP in rats involving analysis of the radioactive contents from the brain, 
heart, liver, lung, and blood to determine the metabolic fate of the ligand and the identity of the 
species which may be responsible for binding to the muscarinic receptor. 
5 
MA TERIALS AND METHODS 

General. All chemicals and solvents were analytical grade and were used without further 
purification. Sep-Pak cartridges (CIS) were purchased from Waters, Inc. Fine filtration filters (0.22 
micro, Millex -GS) were purchased from Millipore Corporation. Thin layer chromatographic analyses 
(TLC) were performed using 250 micron layers of Silica Gel coated on aluminum sheets (Merck, 
Inc.) Three solvent systems were used: System A, chloroform:methanol (S5 : 15) Rr=O.4; System B, 
chloroform: methanol (70:30) Rr=O.S; System C, chloroform:acetic acid (70:30} R =0.4. For 
radiochemical analyses, the plates were marked into ten equal sections and the sample applied. After 
development and drying, the plates were cut into sections which were then counted in a Packard 
Minaxi Model 5000 sodium iodide auto gamma counter. High performance liquid chromatographic 
(HPLC) analyses were performed using a Waters Nova Pak (C-lS silica; 7.Smm x 30 cm) column 
with an on-line Beckman Model 170 Radioisotope Detector. 
Thin-layer chromatography is an analytical technique used to determine the identity of compounds 
based on the strength of their attachment to a medium, which is related to polarity and other 
properties. A mixture of compounds is placed onto an adsorbant, which is then placed upright in a 
developing chamber containing eluant (solvent). The solvent moves up the adsorbant by capillary 
action, moving different compounds at different rates. The greater the polarity of a compound, the 
more slowly it travels. The adsorbant is removed when the solvent front approaches the top of the 
plate, and is allowed to dry. 
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The resulting spots are visualized by placing the plate under UV light, which will show any UV­
sensitive compounds; a stain may be used. The distance a compound travels, divided by the distance 
the solvent travels, is called the relative mobility (Rr value), which is characteristic of a compound in 
a particular solvent and can be used for identification. 
Preparation of FBr]-Z-(R,R)-BrQNP and [82Br]-E-(R,R)-BrQNP. The bromine-82-labeled test 
agents were prepared and purified for these studies by Mr. A.L. Beets and Dr. H. Luo as previously 
described [6] in 42% radiochemical yield with radiopurity ofgreater than 98%. Purification of [82J3r]_ 
Z-(R,R)-BrQNP was performed using a Waters Uporasil semi-preparative (7.8mm x 30 cm) column 
utilizing a mobile phase of methylene chloride:ethanol:triethylamine (98:2:0.1). 
Biodistribution Studies. Female Fischer VAF rats were used to perform tissue distribution studies. 
The animal care and use procedures were reviewed and approved by the Oak Ridge National 
Laboratory Animal Care and Use Committee (ACUC), and were in accordance with "The Guide for 
the Care and Use of Laboratory Animals" and the Animal Welfare Act. For these experiments, 
[~r]-Z-(R,R)-BrQNP and [82Br]-E-(R,R)-BrQNP (1) were dissolved in 100 microliters of ethanol, 
followed by addition of 100 microliters of a O.IN HCI solution and dilution to 10 mL with normal 
saline followed by Millipore filtration. Administration, performed by Dr. H. Luo and Ms. K.R. 
Ambrose, was via intravenous injection into a lateral tail vein of metofane-anesthetized rats (21 
microcuries/rat). The rats were divided into four groups of three each, and were allowed food and 
water ad libitum prior to and during the course ofthe studies. Metabolism cages were set up for one 
group of rats, with the urine and feces being collected daily for seven days. The three remaining 
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groups ofrats were anesthetized with metofane and euthanized by cervical fracture at 15 minutes, one 
hour, and four hours after injection of l. The brain, heart, lung, and liver tissues were removed, 
rinsed with saline, blotted dry, and weighed in tared vials. After removal of the heart, heparinized 
blood samples were obtained from the chest cavity. The samples were then counted in a Packard 
Minaxi 5000 sodium iodide auto gamma counter. 
Tissue Extraction and Analysis. Tissue samples from rats administered Z-(R,R)-BrQNP were 
extracted by the Folch technique using a loose-fitting Potter-Elmejahn ground glass homogenizer. 
Chilled brain and heart samples were finely mince in a watch glass, followed by homogenization for 
three minutes in 10 mL of a 2:1 chloroform-methanol mixture. Following weighing, 0.5-1 gm 
aliquots of liver samples were taken (because of the large tissue mass). These smaller samples were 
minced and extracted in the same manner as the brain and heart samples. Blood samples were 
heparinized, centrifuged, and the plasma samples then homogenized and extracted. 
Filter paper was used to filter the extracts into centrifuge tubes. The filters were then washed with 
an additional mL of the chloroform-methanol mixture. Two mL of normal saline were added, and 
the filtrates were thoroughly mixed and centrifuged at low speed for 8 minutes to separate the organic 
(lower) and aqueous layers. The organic layers were removed with a pipette, filtered through a layer 
of anhydrous sodium sulfate, and evaporated to dryness under an argon stream. The evaporated 
organic and aqueous fractions and the filter paper containing the tissue pellet were then counted in 
a gamma counter. The organic residues were analyzed by Z-(R,R)-BrQNP by thin-layer 
chromatography using silica gel-coated aluminum sheets using a solvent system of 
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chloroform:methanol (85 :15) ~=0.4 . After development, the sheets were dried, cut into ten 
segments, and counted. A control sample of pure [K2BrJ-Z-(R,R)-BrQNP was subjected to the same 
extraction and TLC procedures to serve as a control sample. 
Urine and Fecal Analyses. Urine and feces were collected daily for seven days. Samples ofurine 
from days 1-7 were applied to silica gel plates and analyzed in the solvent system. Aliquots offeces 
from days 1-7 were extracted as described earlier and the organic and aqueous fraction analyzed with 
solvent system C. 
RESULTS 
The biodistribution data demonstrate high cardiac and cerebral uptake of both the E and Z isomers 
of(R,R)-BrQNP (Tables 1 and 2). However, the activity washes out at a rapid rate, and equilibrates 
to a level lower than that of the blood in four hours. Analysis of heart aqueous extracts showed an 
increase, over time, to a value of approximately 26% by four hours. Analysis of the brain extracts 
indicated that approximately 72% of the extractable activity was in the organic layer (Table 3). The 
heart organic extracts contained approximately 70% of extractable activity (Table 4). TLC analysis 
of tissue extracts suggests that greater than 90% was metabolized in the brain tissue after 240 
minutes (Figures 4-12). Similarly, greater than 80% was metabolized in the heart (Figures 13-21). 
Brain aqueous extracts exhibited a relatively constant level of activity. Two minor components were 
also observed, one more polar and one less polar than BrQNP, which slowly increased with time. 
The identity ofthese compounds is unknown but are thought to be metabolites ofBrQNP, due to the 
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time-dependence of their increase. 
Activity levels of the blood, lung, and liver were also measured (Table 5). The lung and liver data 
demonstrated high uptake levels, with a decline in activity to near zero at the end of four hours. 
Minor components were also observed in these tissues by TLC analysis. The blood activity data also 
demonstrated a rapid decline, down to less than 5% of BrQNP remaining, aside from the minor 
components. 
Rapid excretion of radioactivity was observed in the urine and feces, the majority of which was 
excreted through the urine (Figures 22 and 23). Extraction studies indicated that the majority of the 
activity was associated with either the aqueous fraction or the pellet. TLC analysis of the aqueous 
soluble fraction indicated a polar metabolite which migrated in a broad radioactive band centered at 
Rr=O.50. 
DISCUSSION 
Thin-layer chromatographic analysis of extracts of homogenates of brain tissue removed from rats 
3 hours following intravenous administration ofiodine-125-labeled (R,R)-4-IQNB have shown the 
presence ofboth the unmetabolized parent compound and also unknown metabolites increasing with 
time [1]. The distribution and identity of specific metabolites of IQNB in other tissues has not been 
studied in detail. However, polar hydrophilic components have been observed in the aqueous phase 
of plasma extracts, which may represent glucuronide conjugates. Analysis of the ethyl acetate 
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extracts by TLC has shown the presence of small amounts of hydrophobic metabolites, one more 
polar and one less polar than IQNB. 
Recent studies with P23I]-E-(R,R)-IQNP have demonstrated that this ligand has high affinity for the 
Ml muscarinic subtype. It appears to be an attractive new agent for receptor imaging in humans. The 
results ofthese studies indicated that unmetabolized E-(R,R)-IQNP was the only radioactive species 
observed in the brain up to 24 hours. The high receptor binding and lack of metabolites in the brain 
suggest possibilities for the clinical evaluation ofM l muscarinic receptors by SPECT [7]. 
A major purpose ofthe present study was to examine the metabolism of the radiobrominated Z-(R,R) 
isomer ofBrQNP in rat tissues in vivo. Extracts ofbrain, heart, lung, liver, and blood were analyzed 
at three time points after intravenous administration ofbromine-82 labeled Z-(R,R)-BrQNP in order 
to determine the time course of formation of metabolites, if any, and to determine the species which 
was binding at the receptor site. In this initial study, TLC analyses of extracts from the 
aforementioned tissues demonstrated that uptake ofBrQNP was rapid by the liver, lung, and heart. 
Two additional components were observed, one less polar and one more polar than BrQNP, as 
expected, with the less polar being the predominant. It is not surprising to observe relatively rapid 
myocardial washout of activity since the heart mainly contains the M2 receptor subtype [1]. The 
expected result was to see a majority ofunmetabolized compound in the cerebral tissue. However, 
in this study, metabolites were detected in all tissues examined, including the brain. 
One group ofanimals was housed in metabolism cages for one week which permitted urine and feces 
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to be collected to analyze excretion ofactivity and to obtain infonnation by chromatographic analysis. 
A majority of the activity was excreted within the first day, with higher urinary excretion than fecal 
(Figures 22, 23). Folch extracts of the urine and feces indicated that a great majority of the activity 
in both urine and feces was not extracted in the organic phase (Table 6). 
CONCLUSION 
This study examined the in vivo uptake of activity after intravenous injection ofbromine-82 labeled 
E-(R,R) and Z-(R,R)-BrQNP, a high affinity muscarinic ligand, in the heart, brain, blood, liver, and 
lung. The analysis was done by TLC. In addition, the excretion of activity in urine and feces was 
studied over 7 days. The majority of the unmetabolized ligand was washed out of the tissues in the 
period ofone hour, with a slower wash out after one hour and an increasing concentration of a less 
polar metabolite and, to a lesser extent, a more polar metabolite, over time. The activity observed 
was due to unidentified metabolic products and not to the accumulation ofZ-(R,R)-BrQNP in the 
tissues. This lack of receptor binding and high presence of metabolites suggests that the Z-(R,R) 
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Figure 4. Metabolism of BrQNP in brain after 15 minutes (group 1). 
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Figure 5. Metabolism of BrQNP in brain after one hour (group 1). 
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Figure 18. Metabolism of BrQNP in heart after four hours (group 2). 
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Figure 23. Analysis of activity excreted via feces. 
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Table 1. Rat Tissue Distribution Data for [82-Br]-Z-(R,R)-BrQNP 

Percent Injected Dose/gram +/- Standard Deviation 

Tissue 15 min. 60 min. * 240 min. 
Blood 0.727 +/- 0.11 0.824 - 0.891 1.107 +/- 0.10 
Brain 1.653 +/- 0.12 1.654 - 2.077 1.837 +/- 0.09 
Heart 2.033 +/- 0.09 1.4779 - 1.581 0.924 +/- 0.12 
Liver 2.046 +/- 0.09 1.296 - 1.522 1.169 +/- 0.09 
Lung 9.051 +/- 1.63 2.556 - 3.919 1.056 +/- 0.04 
Table 2. Rat Tissue Distribution Data for [82-Br]-E-(R,R)-BrQNP 

Percent Injected Dose/gram +/- Standard Deviation 

Tissue 15 min. * 60 min. 240 min. 
Blood 0.301 - 0.517 0.558 +/- 0.06 0.551 +/- 0.08 
Brain 0.792-1 .019 1.305 +/- 0.28 0.892 +/- 0.09 
Heart 0.883 - 1.258 0.992 +/- 0.14 0.353 +/- 0.06 
Liver 1 .179 - 1.788 1.503 +/- 0.19 1.354 +/- 0.06 
Lung 4.723 - 5.759 2.179 +/- 0.22 0.574 +/- 0.04 
n=3 rats/group *only two rats/group 
Table 3. Brain Extraction Data for [82-Br]-Z-(R,R)-BrONP 
Percent of Total Activity 
Extract 15 min 60 min 240 min 
Organic 72 +/- 9.1 60.3 +/- 9.1 63 +/- 7.2 
Aqueous 8.7 +/- 5.7 5.7 +/- 3.5 7.3 +/- 4.0 
Pellet 19 +/- 4.4 34 +/- 11.1 30 +/- 10.6 
Table 4. Heart Extraction Data for [82-Br]-Z-(R,R)-BrONP 

Percent of Total Activity 

Extract 15 min 60 min 240 min 
Organic 70 +/- 4.2 61.7 +/- 8.4 46.7 +/- 5.8 
Aqueous 10 +/- 5.7 12.3 +/- 4.9 26 +/-1 .7 
Pellet 19 +/- 4.4 26 +/- 12.1 27.3 +/- 6.7 
n=3 rats/time point 
Table 5. Tissue Extraction Data for [82-Br]-Z-(R.R)-BrQNP 

Percent of Total Activity 

Time Tissue Organic Aqueous Pellet 
15 min Blood 5 54 41 
Liver 36 28 36 
Lung 74 8 18 
60 min Blood 2 41 57 
Liver 17 24 59 
Lung 61 18 21 
240 min Blood 0.5 33 66 
Liver 9 20 71 
Lung 34 34 32 
Table 6. Excretion kinetics of [82-Br]-Z-(R.R)-BrQNP via urine and feces 
Percent of Total Activity 
Day 1 Day 2 Day 3 Day 4 Day 5 Day6 Day 7 
Urine 48.79 14.12 13.13 8.92 7.45 4.48 3.84 
Feces 60.53 26.8 7.29 2.36 1.36 1.2 0.66 
